Abstract: A high-pressure composite container is provided. At least a plastic-liner is provided with a plastic shell and a metal end encapsulated by the plastic shell. The plastic-liner of the sealing structure only consists of the plastic shell and the metal end, and the sealing structure is simple. The metal end and a bottle mouth valve jointly compress a sealing ring on the bottle mouth valve, so that the sealing ring forms a stable compression amount, and finally the high-pressure gas cylinder has excellent sealing performance. In addition, the metal end and the plastic shell are well positioned both axially and circumferentially. In the case of high and low pressure and temperature alternation, the relative positions of the metal end and the plastic shell do not change, and a sealing surface of the plastic shell does not deform and dislocate.

Abstract: A substrate has an elastomeric film having surfaces and a nonwoven web having fibers, wherein a plurality of fibers is partially embedded in one surface of the film. In addition, a substrate has an elastomeric film and a nonwoven web having fibers, wherein a plurality of fibers is partially embedded in one surface of the film, and wherein the substrate is essentially free of adhesives and film-based microfibers. A method for making a film/nonwoven composite includes providing an elastomeric film traveling in a machine direction; providing a nonwoven web traveling in the machine direction in face-to-face contact with the film, wherein the nonwoven web includes fibers; and impinging the elastomeric film with hydro jets such that at least some of the fibers become embedded in the film.

Abstract: A therapeutic or diagnostic delivery vehicle is provided. The delivery vehicle may include one or more particles, such as microparticles, nanoparticles and stimuli-responsive particles, conjugated to a tropic cell that targets at least one pathological entity or site. In addition. a pharmaceutical composition is provided. The pharmaceutical composition may include, among other things, a particle conjugated to a tropic cell such as those discussed above and at least one diagnostic or therapeutic agent, such as those described herein. In some aspects, the tropic cell may target at least one pathological entity or site. Further, methods for diagnosing, monitoring or treating a pathological condition in a subject are provided. Such methods may include administering a therapeutically effective amount of the pharmaceutical composition to a subject.

Abstract: A therapeutic or diagnostic delivery vehicle is provided. The delivery vehicle may include one or more particles, such as microparticles, nanoparticles and stimuli-responsive particles, conjugated to a tropic cell that targets at least one pathological entity or site. In addition, a pharmaceutical composition is provided. The pharmaceutical composition may include, among other things, a particle conjugated to a tropic cell such as those discussed above and at least one diagnostic or therapeutic agent, such as those described herein. In some aspects, the tropic cell may target at least one pathological entity or site. Further, methods for diagnosing, monitoring or treating a pathological condition in a subject are provided. Such methods may include administering a therapeutically effective amount of the pharmaceutical composition to a subject.

Abstract: A triggerable composition for one-stage, controlled release of a functional chemical includes a functional monomer having a structure selected from the group described herein, wherein R is a polymerizable portion, N+X31 is a quaternary ammonium halide, and R? and R? are hydrocarbon-containing groups, wherein at least one of R? and R? includes a fragrance or a skin active chemical. At least one of R? and R? can be a ketone, R? can be an aldehyde, and R? can be an alcohol.

Abstract: A substrate has an elastomeric film having surfaces and a nonwoven web having fibers, wherein a plurality of fibers is partially embedded in one surface of the film. In addition, a substrate has an elastomeric film and a nonwoven web having fibers, wherein a plurality of fibers is partially embedded in one surface of the film, and wherein the substrate is essentially free of adhesives and film-based microfibers. A method for making a film/nonwoven composite includes providing an elastomeric film traveling in a machine direction; providing a nonwoven web traveling in the machine direction in face-to-face contact with the film, wherein the nonwoven web includes fibers; and impinging the elastomeric film with hydro jets such that at least some of the fibers become embedded in the film.

Abstract: A triggerable composition for two-stage, controlled release of a functional active chemical includes a trigonelline ester of a functional active with at least one hydroxyl group configured to release the functional active through a hydrolysis reaction upon contact with an aqueous medium, and an encapsulation material for encapsulating the trigonelline ester including a functional active, the encapsulation material triggerable to release the trigonelline ester upon the occurrence of an environmental stimulus. In other aspects, a viscous liquid or an absorbent article includes a triggerable composition for two-stage, controlled release of a functional active chemical, the composition including a trigonelline ester of a functional active with at least one hydroxyl group configured to release the functional active through a hydrolysis reaction upon contact with an aqueous medium, and an encapsulation material for encapsulating the trigonelline ester including a functional active.

Abstract: A triggerable composition for two-stage, controlled release of a functional active chemical includes an aldehyde-based functional active incorporated in an organic salt-based acetal that releases the functional active through a hydrolysis reaction upon contact with an aqueous medium, and an encapsulation material for encapsulating the organic salt-based acetal, the encapsulation material triggerable to release or expose the organic salt-based acetal upon the occurrence of an environmental stimulus such as a pH change. The triggerable composition can be included in an absorbent article having at least one absorbent layer or in a viscous liquid such as a lotion, cream, or medicament.

Abstract: A triggerable composition for two-stage, controlled release of a functional active chemical includes a trigonelline ester of a functional active with at least one hydroxyl group configured to release the functional active through a hydrolysis reaction upon contact with an aqueous medium, and an encapsulation material for encapsulating the trigonelline ester including a functional active, the encapsulation material triggerable to release the trigonelline ester upon the occurrence of an environmental stimulus. In other aspects, a viscous liquid or an absorbent article includes a triggerable composition for two-stage, controlled release of a functional active chemical, the composition including a trigonelline ester of a functional active with at least one hydroxyl group configured to release the functional active through a hydrolysis reaction upon contact with an aqueous medium, and an encapsulation material for encapsulating the trigonelline ester including a functional active.

Abstract: A therapeutic or diagnostic delivery vehicle is provided. The delivery vehicle may include one or more particles, such as microparticles, nanoparticles and stimuli-responsive particles, conjugated to a tropic cell that targets at least one pathological entity or site. In addition, a pharmaceutical composition is provided. The pharmaceutical composition may include, among other things, a particle conjugated to a tropic cell such as those discussed above and at least one diagnostic or therapeutic agent, such as those described herein. In some aspects, the tropic cell may target at least one pathological entity or site. Further, methods for diagnosing, monitoring or treating a pathological condition in a subject are provided. Such methods may include administering a therapeutically effective amount of the pharmaceutical composition to a subject.